Latest Intellectual Property News

Terragen Holdings has launched its new probiotic products for ruminants, initiated multiple key trials including methane mitigation and crop yield studies, and secured a US patent allowance, positioning itself for global market expansion.

FBR Limited wraps up its US Demonstration Program, secures $6.3 million in capital, and appoints Mark Pivac as CEO amid a 70% cost reduction drive. Strategic collaborations with Samsung Heavy Industries and Liebherr signal broader automation ambitions.

State Gas Limited advances its Rolleston West Project with successful drilling of two vertical wells confirming coal and gas continuity, aiming to establish a maiden 2P reserve. Concurrently, the company expands its high density natural gas supply, targeting significant revenue growth through a six-truck dual fuel trial.

Inventis Limited reported solid Q3 cash generation and strong technology sales growth, while actively pursuing international expansion and a $2.5 million USD capital raise for its US Hazavoid entity.

KNeoMedia advances toward ASX reinstatement after raising nearly $2.9 million and expanding its KneoScience platform across New York City schools, including a significant new high school content rollout.

Mesoblast has commercially launched Ryoncil in the US for pediatric acute GVHD, backed by a strong cash position and advancing multiple cell therapy programs.

FirstWave Cloud Technology reported a mixed Q3 FY25 with declining cash reserves and ARR but secured a strategic AWS-funded partnership to accelerate cloud service adoption.

Sparc Technologies has progressed to Stage 2 of its Sparc Hydrogen joint venture with pilot plant commissioning slated for mid-2025, while also securing its first patent for photocatalytic water splitting technology in Morocco. Concurrently, its graphene-based additive ecosparc® demonstrates promising field trial results, underpinning commercial momentum.

RBR Group Limited has signed a conditional MOU with Field Ready Group to establish a joint venture focused on employability training in Mozambique, supporting major LNG projects including ExxonMobil’s Rovuma LNG. The venture, through RBR’s subsidiary Futuro Skills, aims to enhance local workforce readiness and economic growth.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Anteris Technologies Global Corp. has filed an amended 10-K to disclose comprehensive governance, executive pay, and related party transactions for fiscal 2024, completing its annual SEC reporting obligations.